|
46. Pharmacokinetics
of anastrozole and tamoxifen alone and in combination during
adjuvant endocrine therapy for early breast cancer in postmenopausal
women: A sub-protocol of the 'Arimidex ® and Tamoxifen
Alone or in Combination'(ATAC)trial. Br J Cancer
2001;85(3):317-24. Abstract
47. Ellis
MJ et al. Letrozole (Femara)is a more effective inhibitor
of estrogen activity than tamoxifen:Evidence from a randomized
phase III trial of 4 months preoperative endocrine therapy
for postmenopausal women with primary invasive breast cancer.
Proc ASCO 2001; Abstract
1661.
48. Geisler
J et al. Influence of neoadjuvant anastrozole (Arimidex)on
intratumoral estrogen levels and proliferation markers in
patients with locally advanced breast cancer. Clin
Cancer Res 2001;7(5):1230-6. Abstract
49. Mouridsen
H et al. Superior efficacy of letrozole versus tamoxifen
as first-line therapy for postmenopausal women with advanced
breast cancer: Results of a phase III study of the International
Letrozole Breast Cancer Group. J Clin Oncol 2001:2596-2606.
Abstract
50. Nabholtz
JM et al. Anastrozole is superior to tamoxifen as first-line
therapy for advanced breast cancer in postmenopausal women:Results
of a North American multi-center randomized trial. J
Clin Oncol 2000;18(22):3758-3767. Abstract
51. Dixon
JM et al. The effects of neoadjuvant anastrozole (Arimidex)
on tumor volume in postmenopausal women with breast cancer:A
randomized, double-blind,single-center study. Clin
Cancer Res 2000;6(6):2229-35. Abstract
OTHER
CLINICAL TRIALS
Randomized,
Double-Blind Study Comparing Arimidex w/Nolvadex As Neoadjuvant
& Adjuvant Treatment in Postmenopausal Women w/Large Operable
[T2(3>cm,T3,N0-2,M0 ] or Potentially Operable, Locally
Adv. (T4B,N0-2,M0),ER+and/or PR+Breast Cx. Protocol
|
